During the recently held Pharmacovigilance Risk Assessment Conference (PRAC), the European Medicines Agency (EMA) revealed results from a study indicating that patients "taking tofacitinib for rheumatoid arthritis and who were at risk of heart disease were more likely to experience a major cardiovascular problem...and had a higher risk of developing cancer." In 3 nearly equivalent patient groups (1455 patients received 5mg of tofacitinib twice daily; 1456 received 10mg of tofacitinib twice daily; 1451 received a TNF inhibitor), incidences of cancer were higher (2.4% for 5mg; 4.2% for 10mg) for those administered tofacitinib vs. 2.5% who received a TNF inhibitor.
To learn more about this study, click here.
Source mentioned: Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med 2022;386:316-326.
No comments:
Post a Comment